MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys $12,414.09 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero acquired 8,931 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $12,414.09. Following the completion of the purchase, the director directly owned 610,842 shares in the company, valued at $849,070.38. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero bought 46,620 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.35 per share, for a total transaction of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero bought 78,239 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $1.39 per share, with a total value of $108,752.21.
• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero purchased 11,899 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Stock Performance

Shares of MAIA opened at $1.33 on Friday. The firm has a market cap of $80.90 million, a PE ratio of -2.15 and a beta of 0.25. MAIA Biotechnology, Inc. has a 52-week low of $0.87 and a 52-week high of $3.19. The business’s 50 day moving average price is $1.37 and its two-hundred day moving average price is $1.43.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Research analysts predict that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares in the last quarter. Centric Wealth Management boosted its position in shares of MAIA Biotechnology by 2.0% during the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after purchasing an additional 11,500 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at about $29,000. Jane Street Group LLC acquired a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at about $52,000. Finally, PVG Asset Management Corp bought a new stake in MAIA Biotechnology in the 1st quarter valued at about $46,000. 5.65% of the stock is currently owned by institutional investors and hedge funds.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.